$NMRA
Neumora Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024027927 Filed on March 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.32M $11.24M $45.48M
YoY Change 47.9% -63.9% 46.13%
% of Gross Profit
Research & Development $45.76M $38.86M $142.7M
YoY Change 55.16% -57.64% 55.55%
% of Gross Profit
Depreciation & Amortization $158.0K $166.0K $668.0K
YoY Change -1.25% -42.76% 13.22%
% of Gross Profit
Operating Expenses $60.07M $50.10M $188.2M
YoY Change 53.37% -59.23% 53.17%
Operating Profit -$60.07M -$252.1M
YoY Change 53.38% 85.54%
Interest Expense $6.365M $5.646M $16.61M
YoY Change 78.29% 23.79% 264.28%
% of Operating Profit
Other Income/Expense, Net $6.353M -$104.0K -$170.0K
YoY Change -21276.67% -125.68% -141.46%
Pretax Income -$53.72M -$108.5M -$235.7M
YoY Change 50.77% -17.14% 80.03%
Income Tax $268.0K $268.0K
% Of Pretax Income
Net Earnings -$53.72M -$108.7M -$235.9M
YoY Change 50.8% -16.94% 80.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34 -$3.63
Diluted Earnings Per Share -$0.34 -$0.71 -$3.63
COMMON SHARES
Basic Shares Outstanding 158.9M 152.7M 65.02M
Diluted Shares Outstanding 157.9M 65.02M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $422.7M $454.0M $454.0M
YoY Change 22.35% 22.07% 22.07%
Cash & Equivalents $182.9M $374.0M $374.0M
Short-Term Investments $239.8M $79.94M $79.94M
Other Short-Term Assets $19.16M $23.36M $23.36M
YoY Change 40.91% 53.67% 53.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables $906.0K $939.0K
Total Short-Term Assets $442.8M $478.3M $478.3M
YoY Change 23.0% 23.28% 23.27%
LONG-TERM ASSETS
Property, Plant & Equipment $1.635M $6.858M $6.858M
YoY Change -83.14% 184.45% -35.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $302.0K $9.845M $9.845M
YoY Change -98.35% -58.11% -58.11%
Other Assets $1.213M $1.213M $1.213M
YoY Change -70.41% -58.36% -70.41%
Total Long-Term Assets $7.426M $17.92M $17.92M
YoY Change -76.87% -53.2% -53.1%
TOTAL ASSETS
Total Short-Term Assets $442.8M $478.3M $478.3M
Total Long-Term Assets $7.426M $17.92M $17.92M
Total Assets $450.2M $496.2M $496.2M
YoY Change 14.82% 16.41% 16.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.492M $337.0K $337.0K
YoY Change 35.64% -95.28% -95.25%
Accrued Expenses $19.49M $24.64M $24.64M
YoY Change -4.45% 113.55% 65.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.61M $25.11M $25.11M
YoY Change 12.89% 5.97% 5.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.060M $2.008M $2.008M
YoY Change -76.44% -64.77% -64.77%
Total Long-Term Liabilities $1.060M $2.008M $2.008M
YoY Change -76.44% -64.77% -64.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.61M $25.11M $25.11M
Total Long-Term Liabilities $1.060M $2.008M $2.008M
Total Liabilities $25.67M $27.12M $27.12M
YoY Change -2.4% -7.75% -7.76%
SHAREHOLDERS EQUITY
Retained Earnings -$757.2M -$703.4M
YoY Change 50.46%
Common Stock $1.182B $1.173B
YoY Change 5370.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $424.5M $469.1M $469.1M
YoY Change
Total Liabilities & Shareholders Equity $450.2M $496.2M $496.2M
YoY Change 14.82% 16.41% 16.42%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$53.72M -$108.7M -$235.9M
YoY Change 50.8% -16.94% 80.23%
Depreciation, Depletion And Amortization $158.0K $166.0K $668.0K
YoY Change -1.25% -42.76% 13.22%
Cash From Operating Activities -$42.96M -$51.44M -$163.3M
YoY Change 30.01% -8.35% 42.1%
INVESTING ACTIVITIES
Capital Expenditures $775.0K $4.634M $4.707M
YoY Change 1837.5% 2989.33% -65.16%
Acquisitions
YoY Change
Other Investing Activities -$149.2M $18.31M $69.09M
YoY Change -5336.0% 107.61% -144.72%
Cash From Investing Activities -$150.0M $13.68M $64.39M
YoY Change -5419.18% 57.75% -138.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $235.7M
YoY Change 102.37%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.845M -481.0K 231.9M
YoY Change 1745.0% -100.42% 100.39%
NET CHANGE
Cash From Operating Activities -42.96M -51.44M -163.3M
Cash From Investing Activities -150.0M 13.68M 64.39M
Cash From Financing Activities 1.845M -481.0K 231.9M
Net Change In Cash -191.1M -38.25M 133.0M
YoY Change 534.5% -157.47% -179.59%
FREE CASH FLOW
Cash From Operating Activities -$42.96M -$51.44M -$163.3M
Capital Expenditures $775.0K $4.634M $4.707M
Free Cash Flow -$43.73M -$56.08M -$168.0M
YoY Change 32.19% -0.36% 30.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001885522
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1274
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41802
CY2023 dei Entity Registrant Name
EntityRegistrantName
NEUMORA THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4367680
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
490 Arsenal Way
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023 dei City Area Code
CityAreaCode
857
CY2023 dei Local Phone Number
LocalPhoneNumber
760-0900
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
NMRA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
158886101
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young
CY2023 dei Auditor Location
AuditorLocation
San Jose
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
374038000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
240943000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
79944000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
130941000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24297000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16021000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
478279000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
387955000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9845000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
23511000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1790000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2411000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5068000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8231000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2913000
CY2023Q4 us-gaap Assets
Assets
496195000
CY2022Q4 us-gaap Assets
Assets
426234000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
337000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7147000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21257000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11536000
CY2023Q4 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
139000
CY2022Q4 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
1644000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3378000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3370000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25111000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23697000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1853000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5072000
CY2023Q4 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
155000
CY2022Q4 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
628000
CY2023Q4 us-gaap Liabilities
Liabilities
27119000
CY2022Q4 us-gaap Liabilities
Liabilities
29397000
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
50000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
820349000
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
104417000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
104417000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
843687000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1210000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
158832000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
158832000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32612000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32612000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1172570000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
21430000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-76000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-774000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-703434000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-467509000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
469076000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-446850000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
496195000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
426234000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
142719000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91749000
CY2023 nmra Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
63904000
CY2022 nmra Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
13000000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45475000
CY2022 us-gaap Profit Loss
ProfitLoss
-130904000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31121000
CY2023 us-gaap Operating Expenses
OperatingExpenses
252098000
CY2022 us-gaap Operating Expenses
OperatingExpenses
135870000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-252098000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-135870000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
16611000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4561000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-170000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
405000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16441000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4966000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-235657000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-130904000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
268000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-235925000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130904000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
698000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-774000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-235227000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-131678000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.81
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.81
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65021000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65021000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27207000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27207000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-325221000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
612000
CY2022 nmra Issuance Of Common Stock Value As Noncash Consideration Related To An Acquisition Of Assets
IssuanceOfCommonStockValueAsNoncashConsiderationRelatedToAnAcquisitionOfAssets
24000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1115000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-774000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8298000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130904000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-446850000
CY2023 nmra Conversion Of Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Value
ConversionOfConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingValue
843687000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
226524000
CY2023 nmra Issuance Of Common Stock Value Upon Achievement Of Milestone Related To Acquisition Of Assets
IssuanceOfCommonStockValueUponAchievementOfMilestoneRelatedToAcquisitionOfAssets
58539000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2856000
CY2023 nmra Sale And Issuance Of Common Stock
SaleAndIssuanceOfCommonStock
810000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1497000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
698000
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
17240000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-235925000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
469076000
CY2023 nmra Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
63904000
CY2022 nmra Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
13000000
CY2023 us-gaap Profit Loss
ProfitLoss
-235925000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
17240000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
8298000
CY2023 nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
3355000
CY2022 nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
2103000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
668000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
594000
CY2023 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
3741000
CY2022 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
708000
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
18000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-559000
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-120000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-246000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11401000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3628000
CY2022 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1373000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-581000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1246000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6486000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1621000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3403000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1826000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-163278000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-114896000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
109072000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
226369000
CY2023 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4590000
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
13000000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
178166000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
71867000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
117000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
511000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
64387000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-168013000
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
232565000
CY2022 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
112216000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
810000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2856000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2658000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1613000
CY2023 nmra Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
491000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3804000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
744000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231936000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
115743000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
133045000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-167166000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242206000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
409372000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
375251000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242206000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
374038000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
240943000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1213000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1263000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
375251000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
242206000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
192000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8865000
CY2022 nmra Offering Costs Related To Initial Public Offering Included In Accounts Payable And Accrued Liabilities
OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities
340000
CY2023 nmra Acquisition Of Assets Included In Accounts Payable And Accrued Liabilities
AcquisitionOfAssetsIncludedInAccountsPayableAndAccruedLiabilities
775000
CY2023 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
843687000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
44000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
505000
CY2023 nmra Issuance Of Common Stock Upon Achievement Of Milestone Related To Acquisition Of Assets
IssuanceOfCommonStockUponAchievementOfMilestoneRelatedToAcquisitionOfAssets
58539000
CY2023Q4 nmra Number Of Clinical And Preclinical Neuroscience Programs
NumberOfClinicalAndPreclinicalNeurosciencePrograms
7
CY2023 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
7.8463-for-1
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair value of the Company’s convertible preferred stock, the fair value of the Company’s common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company’s estimates.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents deposited in accounts at several financial institutions that may exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents to the extent recorded in the consolidated balance sheets. The Company believes it is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held.</span></p>
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2900000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2023 nmra Uncertain Tax Positions Description
UncertainTaxPositionsDescription
The Company recognizes and measures uncertain tax positions using a two-step approach. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
452119000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
26000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
102000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
452043000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
338579000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
775000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
337805000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
79944000
CY2023Q4 nmra Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
9845000
CY2023Q4 nmra Estimated Fair Value Of Available For Sale Debt Securities Fair Value
EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue
89789000
CY2023Q4 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
1
CY2023Q4 nmra Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
19085000
CY2022Q4 nmra Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
13484000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4273000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1618000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
939000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
919000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24297000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16021000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3184000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2957000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1435000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1060000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1790000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2411000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10011000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8400000
CY2023Q4 nmra Accrued Research And Development Services Due To Related Party
AccruedResearchAndDevelopmentServicesDueToRelatedParty
3100000
CY2022Q4 nmra Accrued Research And Development Services Due To Related Party
AccruedResearchAndDevelopmentServicesDueToRelatedParty
0
CY2023Q4 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
5004000
CY2022Q4 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
889000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1187000
CY2023Q4 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
4705000
CY2022Q4 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
652000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
750000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
408000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21257000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11536000
CY2023Q3 nmra Additional Space Added To Area Of Office And Laboratory As Per Amendment
AdditionalSpaceAddedToAreaOfOfficeAndLaboratoryAsPerAmendment
972
CY2023 us-gaap Payments For Rent
PaymentsForRent
4300000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
300000
CY2022 us-gaap Payments For Rent
PaymentsForRent
3500000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1100000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3719000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1892000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5611000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
380000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5231000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3378000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1853000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
4071000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2486000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q3 nmra Operating Lease Liability Derecognized
OperatingLeaseLiabilityDerecognized
700000
CY2022Q3 nmra Right Of Use Asset Derecognized
RightOfUseAssetDerecognized
600000
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
820349000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
104417000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
104417000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
843687000
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
856756000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29170000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.896
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.965
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.872
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.911
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.049
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.017
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17240000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8298000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.028
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2023 nmra Effective Income Tax Rate Reconciliation Milestone Payments Percent
EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent
-0.053
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.009
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.005
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.021
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.021
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.036
CY2023 nmra Effective Income Tax Rate Reconciliation State Rate Adjustments
EffectiveIncomeTaxRateReconciliationStateRateAdjustments
0.005
CY2022 nmra Effective Income Tax Rate Reconciliation State Rate Adjustments
EffectiveIncomeTaxRateReconciliationStateRateAdjustments
0.022
CY2023 nmra Effective Income Tax Rate Reconciliation Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
-0.0002
CY2022 nmra Effective Income Tax Rate Reconciliation Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
-0.003
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.237
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.282
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
79117000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
63937000
CY2023Q4 nmra Deferred Tax Assets In Capitalized License Agreements
DeferredTaxAssetsInCapitalizedLicenseAgreements
41032000
CY2022Q4 nmra Deferred Tax Assets In Capitalized License Agreements
DeferredTaxAssetsInCapitalizedLicenseAgreements
39113000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
57872000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
26132000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12981000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8425000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5942000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3496000
CY2023Q4 nmra Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1429000
CY2022Q4 nmra Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
2080000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
407000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
467000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
198780000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
143650000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
197280000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141557000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1500000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2093000
CY2023Q4 nmra Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
1385000
CY2022Q4 nmra Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
2028000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
115000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
65000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1500000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2093000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
55700000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
37100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8176000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7821000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
391000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
355000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
97000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8664000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8176000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-235925000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130904000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65021000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65021000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27207000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27207000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.81
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.81
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15741000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
117294000
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.50
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.03

Files In Submission

Name View Source Status
0000950170-24-027927-index-headers.html Edgar Link pending
0000950170-24-027927-index.html Edgar Link pending
0000950170-24-027927.txt Edgar Link pending
0000950170-24-027927-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img234951805_0.jpg Edgar Link pending
img234951805_1.jpg Edgar Link pending
img234951805_2.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img234951805_3.jpg Edgar Link pending
img234951805_4.jpg Edgar Link pending
img234951805_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nmra-20231231.htm Edgar Link pending
nmra-20231231.xsd Edgar Link pending
nmra-ex10_22.htm Edgar Link pending
nmra-ex10_23.htm Edgar Link pending
nmra-ex23_1.htm Edgar Link pending
nmra-ex31_1.htm Edgar Link pending
nmra-ex31_2.htm Edgar Link pending
nmra-ex32_1.htm Edgar Link pending
nmra-ex32_2.htm Edgar Link pending
nmra-ex97_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nmra-20231231_htm.xml Edgar Link completed